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Purpose: In the past decade, novel psychoactive substances (NPSs) gained a signiﬁcant role on the contemporary drug
scene. Synthetic cathinones and synthetic cannabinoids are the most common NPSs both in Hungary and worldwide.
This study aims to provide a literature review on the Hungarian characteristics related to the use of these NPSs.
Materials and methods: Available literature regarding synthetic cathinone and cannabinoid use in Hungary was
overviewed and structured into (a) epidemiological studies, (b) studies on the subjective and somatic effects, and
(c) studies on toxicity and adverse consequences. Published papers between 2007 and 2017 were identiﬁed using
PubMed and MATARKA search engines. Results: One hundred twenty-six papers were identiﬁed and after exclusion,
54 papers remained for in-depth analysis. Most of the reviewed studies were providing epidemiological information
regarding the NPSs of our interest. Hungarian prevalence rates were not higher than the European averages. Identiﬁed
risks of these NPSs consisted of drug-induced psychosis, further severe psychiatric symptoms, and fatal overdose.
Injecting of cathinones was also a commonly reported phenomenon, mostly among clients of needle-exchange
programs. Conclusion: Based on the reviewed body of research, necessary information is available to plan effective
prevention and intervention programs and establishes speciﬁc therapeutic guidelines for the treatment of NPS users.
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INTRODUCTION
In the past decade, novel psychoactive substances (NPSs)
gained a signiﬁcant role on the contemporary drug scene.
With a decreasing purity and availability of 3,4-
methylenedioxymethamphetamine (MDMA), cocaine, or
heroin, NPSs such as synthetic cathinones became preferred
alternates of already banned substances.
The European Monitoring Centre for Drugs and Drug
Addiction currently monitors more than 450 NPSs [1],
including phenethylamines, opioids, tryptamines, benzo-
diazepines, arylalkylamines, and piperazines, yet highest
prevalence rates were found regarding the use of synthetic
cathinones and synthetic cannabinoids both in the adult/
general [2] and adolescent populations [3]. The majority of
the published prevalence rates regarding NPS use were
derived from seizure data or studies that examined non-
representative samples– e.g., club-goers or the gay community;
therefore, these results need to be considered as rough estimates
due to the lackof standardisedmeasures.Nevertheless, between
2008 and 2013, a sevenfold increase in the number of seized
NPS was reported across Europe [1]. Among synthetic
cathinones, mephedrone (4-methylmethcathinone), pentedrone
[2-(methylamino)-1-phenylpentan-1-one], methylone (3,4-
methylenedioxy-N-methylcathinone), 4-methylethcathinone
(4-MEC), and 3,4-methylenedioxypyrovalerone (MDPV)were
the most frequently consumed substances, whereas JWH-type
products [e.g., JWH-018: (1-pentyl-3-(1-naphthoyl)indole)]
were the most popular synthetic cannabinoids in the past few
years.
Growing popularity of NPSs can be explained by
several factors, including their easy availability, relative-
ly low price, or the fact that they can give a better quality
higher than formerly banned psychoactive substances [4].
Easy access to these drugs is further facilitated by the
globalisation of the web, thus the widespread marketing
of NPSs through online platforms.
An increasing injection rate of synthetic cathinones can
also be mentioned as a novel public health concern. A
tendency to inject mephedrone or MDPV was reported by
several countries, such as Hungary, Austria, Romania,
Slovenia, and Ireland [5–9].
This study aims to provide a brief overview of Hungary’s
NPS-related characteristics by searching the literature of the past
10 years, as 2007 was the ﬁrst year when mephedrone entered
the drug scene, followed by the burst of NPS drug market.
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MATERIALS AND METHODS
We overview the most relevant ﬁndings of the available
literature regarding NPS use characteristics in Hungary and
present these results by the following structure: (a) epide-
miological studies, (b) studies on the subjective and somatic
effects, and (c) studies on toxicity and adverse
consequences.
Published papers between January 1, 2007 and September
18, 2017 were identiﬁed using PubMed for international
publications (or papers with an English abstract) and
MATARKA search engine for national publications, applying
the keywords: “NPS/ÚPSZ” or “Novel Psychoactive Sub-
stance*/Új Pszichoaktív Szer*” or “cathinone*/katinon*” or
“mephedrone/mefedron” or “MDPV” or “pentedrone/
pentedron*” or “methylone/metilon*” or “4-MEC” or “syn-
thetic cannabinoid/szintetikus kanninoid*” or “JWH*” and
“Hungar*”. Since synthetic cathinones and cannabinoids were
the most popular NPSs both in Hungary and worldwide, we
focused only on these substances during our search process.
RESULTS
As a result, 100 papers were identiﬁed through PubMed and
26 papers through MATARKA. As the next step, altogether
90 papers were excluded from the analysis. Major reason of
exclusion (n of exclusion = 56) was irrelevant content
[e.g., papers using the abbreviation “NPs” for “nanoparti-
cles” (n= 37) or “neuropeptide S” (n= 2), “natural pro-
ducts” (n= 2), “nasal powders” (n= 1), “nail psoriasis
severity” (n= 1), “neuropsychiatric symptoms” (n= 1),
“new principles” (n= 1), “nasal polyposis” (n= 1) or
“agricultural non-point (diffuse) sources” (n= 1) and not
for “novel/new psychoactive substances”, or the term
“ÚPSZ” for “Új Pedago´giai Szemle” (n= 3) instead of
“Új Pszichoaktív Szer”, or the term “MDPV” for “Muscovy
duck parvovirus” (n= 2) instead of “methylenedioxypyro-
valerone” or “MEC” for a Hungarian media agency (n= 3)
or the “mecA gene” (n= 1) instead of “methylethcathi-
none”]. In case of six papers, an overlap was observed
between PubMed and MATARKA search results and there-
fore labelled as “duplicate results”. Further exclusions
derived from the fact that the excluded papers were provid-
ing a general overview of NPSs and their legislative system
and did not present Hungarian speciﬁcities (n= 15), or
presented the effects of NPSs using animal models
(n= 5), or introduced state-of-the-art analytical methods for
toxicology (n= 6). One study dealt with kratom – labelled
as NPS – but not with synthetic cathinones or cannabinoids,
whereas another study focused on the endogenous cannabi-
noid system, instead of the effects of synthetic cannabinoids.
After exclusion, 36 papers remained in the analysis for
in-depth review. With regard to epidemiological data,
annual reports of the Hungarian National Focal Point
(n= 10) were additionally reviewed in the same time period
(2007–2017), as these papers were not identiﬁed either
through PubMed, or through MATARKA search results.
Annual reports of the Hungarian National Focal Point were
screened in order to identify further publications. As a result,
eight additional papers were included.
Therefore, altogether 54 papers remained for review.
Figure 1 presents the ﬂowchart of the search protocol and
the steps of paper exclusion/inclusion.
Figure 1. Flowchart of the review process
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Epidemiological studies
With regard to the epidemiological aspects of either syn-
thetic cathinone or cannabinoid consumption, many of the
reviewed studies provided estimates by analysing biological
samples of substance users. Árok et al. [10] examined the
urine/blood samples of 2,976 suspected drug users in
South-East Hungary between 2008 and 2015. A total of
1,777 subjects provided a positive test for any psychoactive
substances. Based on their results, the most frequently used
synthetic cathinone was mephedrone in 2010 (n of positive
tests = 13), 4-MEC (n of positive tests= 31), methylone
(n of positive tests= 28), MDPV (n of positive tests= 25),
4-ﬂuoromethcathinone (n of positive tests = 12), and
4-ﬂuoroamphetamin (n of positive tests= 9) in 2011, as
well as pentedrone between 2012 and 2015 (n range of
positive tests= 38–73). Authors further added that the
frequency of substances in the assessed biological samples
was comparable to seizure rates as well. Members of the
same research group [11] found that pentedrone was the
most commonly used stimulant NPS in Budapest as well –
not just in the region of southeast Hungary. The increase in
the number of pentedrone-related positive biological sam-
ples was associated with a change in the legislative status of
mephedrone, MDPV, methylone, or 4-MEC. In line with
these ﬁndings, To´th et al. [12] identiﬁed a 7% prevalence of
mephedrone use in 2010 by assessing 5,386 samples derived
from participants of Budapest and Szeged, indicating that
this NPS was still popular in that year. The emergence of
mephedrone consumption between 2008 and 2010 was
conﬁrmed by Ujváry [13] as well. The assessment of
biological samples in order to identify synthetic cannabinoid
products was not reported by these studies. Regarding the
national legislative system, Ujváry [14, 15] described that in
case of synthetic cannabinoids, head shops terminated the
distribution of these products after 2008, due to the inter-
ventions of the National Public Health and Medical Ofﬁcer
Service (ÁNTSZ). In 2011, ﬁve JWH types were registered
in the B-list, whereas in 2012, further synthetic cannabinoid
products entered the C-list of legislation [15]. In case of
synthetic cathinones, mephedrone was banned in January
2011, followed by the legislation of other cathinone
derivatives.
Considering further epidemiological data, ﬁrst mention
of either synthetic cathinone or cannabinoid use occurred in
the 2010 annual report of the Hungarian National Focal
Point [16], although without providing exact prevalence
rates. As cited by the 2011 annual report [16] as well, the
Health Behaviour in School-aged Children study [17] iden-
tiﬁed a lifetime prevalence rate of synthetic cathinone use
below 1% in 2010. However, in 2011, the European School
Survey Project on Alcohol and Other Drugs (ESPAD) study
found a 6% lifetime prevalence rate of mephedrone use
among school-aged respondents [18]. The ﬁndings of the
2014 HBSC study [19] showed a 4.5% lifetime prevalence
of NPS use (including synthetic cathinones), indicating a
signiﬁcant increase since 2010. According to the results of
the 2015 ESPAD study [20], lifetime prevalence of synthet-
ic cannabinoids was 10.1%; therefore, this NPS reached the
second place in the consumption structure of school-aged
respondents. In 2015, NPS use of the general population
was also examined [21]. Lifetime prevalence was 1.9% for
synthetic cannabinoid use and only 0.6% for mephedrone.
The 2012 annual report of the Reitox National Focal
Point [16] presented an increase in the frequency of syn-
thetic cannabinoid seizures between 2010 (5 kg) and 2011
(51 kg) as well as in the case of synthetic cathinones seizures
(from 2010: 353 kg to 2011: 595 kg), based on the data
provided by the Hungarian Institute for Forensic Sciences
(BSZKI). The frequency of seizures regarding either syn-
thetic cannabinoids (from 2011: 51 kg to 2012: 61 kg) or
cathinone derivatives (from 2011: 595 kg to 2012: 700 kg)
further increased between 2011 and 2012 [16]. This increas-
ing tendency remained throughout the following years [16].
In 2011, among 66 drug-using women [either pregnant or
with a child(ren) below the age of 2], 28.8% used mephe-
drone, 25.8% used MDPV, and 6.1% used synthetic can-
nabinoids at least once in their lifetimes [22]. In 2012,
among 44 drug-using women [either pregnant or with a
child(ren) below the age of 2], 63.6% used MDPV, 50%
used pentedrone, 36.4% used mephedrone, and 34.1% used
synthetic cannabinoids at least once in their lifetimes [22].
The prevalence rates of synthetic cathinone use were also
observed among the clients of needle-exchange programs
(NEPs). Csák et al. [23] gathered information from
16 Hungarian-registered NEPs regarding the substance-use
characteristics of their clients. As a result, all NEPs reported
mephedrone use in 2010 and among clients of 14 NEPs,
intravenous mephedrone use was also observed. Csák et al.
[9] described a shift to injecting MDPV in 2011, with 48.1%
of injecting drug user (IDU) clients of the Blue Point NEP
intravenously administering this cathinone derivative. This
shift to injecting cathinones was conﬁrmed by the study of
Péterﬁ et al. [24] as well. Clients of the Blue Point NEP were
asked to provide information about their substance-use
habits between 2006 and 2014 (n= 3,680) [25]. Based on
these responses, it was found that between 2010 and 2014,
NPS (mainly synthetic cathinones) gained dominant preva-
lence among IDUs, with 80% of the IDUs injecting NPS.
Rácz and Csák [26] in their study highlighted the risks of
NPS injecting, including the fact that these substances often
contain unknown compounds and may induce unpredictable
effects and adverse consequences. Tarján et al. [27] also
emphasised the risks of increasing hepatitis C virus (HCV)
prevalence, syringe reuse, or daily injection times, especial-
ly among NPS injectors. Two papers [28, 29] were dealing
with a potential increase in HCV and HIV prevalence
among IDUs, partly as a response to the decreasing harm
reduction efforts observed in the country (e.g., closing the
largest NEP of Hungary). Tarján et al. [29] described that
the prevalence of HCVwas doubled between 2011 and 2014
among NPS injectors, whereas Rácz et al. [28] presented
new cases of HIV among the clients of two NEPs in
Budapest. As it is summarised, mephedrone was only
dominant among IDUs in 2010 as ﬁrst MDPV, later pente-
drone became the most commonly injected cathinone deri-
vatives in the following years [16]. These ﬁndings are
comparable to the reports of the BSZKI [16] as well.
Related to the phenomenon of discarding used needles,
two recent studies from the same research group [30, 31]
analysed injecting paraphernalia (e.g., discarded syringes)
for drug residues of either diverted medication or NPS.
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Their ﬁndings suggest that between 2015 and 2016 most
common components of the assessed samples (n of study
1= 2,977) were the diverted substitution medication
methadone (32%) and mainly cathinones, such as
pentedrone (18%), mephedrone (13%), alpha-PHP (8%),
and alpha-PEP (5%) [31]. Of the 12,762 compound cases
(n of study 2= 2,985), 50% were cathinones [30].
Corazza et al. [32] presented the outcomes of an inter-
national collaboration, the Recreational Drugs European
Network project, which composed of the qualitative
assessments of websites, drug fora, or other online plat-
forms in eight languages from collaborating countries,
including Hungary for identifying NPS products. The aim
of this study was to explore what types of NPS are being
mentioned in the online scene, as well as to overview user
reports about the effects of these substances. As an out-
come, more than 650 NPS products were identiﬁed, out of
which 220 were synthetic cannabinoids and 30 cathinone
derivatives.
A study by Kapitány-Fövény and Demetrovics [33]
assessed the utility of Google Trends in providing relevant
information about the web-interest toward mephedrone.
This study conﬁrmed the fact that mephedrone reached its
popularity when it was still legal. After its legislation,
web-interest toward this NPS signiﬁcantly dropped.
Instito´ris et al. [34] examined the prevalence of psycho-
active substance use (including NPS consumption) among
Hungarian Driving Under the Inﬂuence of Drugs drivers in
2014 and 2015 (N= 1,252). Positive tests for cathinones
(pentedrone and alpha-PVP) occurred in 21%–28%, where-
as for synthetic cannabinoids in 15%–19% of all cases.
Finally, Kassai et al. [35] – in the framework of a media
monitoring study with qualitative content analysis – pointed
out that NPS use is rather portrayed from an externalised
point of view in the media, emphasising that NPS use is
mainly due to low socioeconomic background and mostly a
problem of the disadvantaged rural communities and a
minority population in general.
Studies on the subjective and somatic effects
In the past 10 years, both quantitative and qualitative studies
assessed the effects of synthetic cathinones and cannabi-
noids. Considering quantitative measures, Kapitány-Fövény
et al. [4] identiﬁed six factors of mephedrone-induced
subjective effects: (a) positive emotions, (b) sensibility,
(c) adverse somatic effects, (d) adverse psychological
effects, (e) stimulant effects, and (f) psychedelic effects.
Based on their results, users (n= 145) mainly prefer psy-
chostimulant and entactogen properties of this NPS. Effects
of mephedrone are similar to the effects of MDMA; there-
fore, synthetic cathninones might function as alternates of
formerly banned psychostimulants. Furthermore, those
users who inject mephedrone show higher dosages and
frequencies of use, higher rates of opiate use, and greater
risks of experiencing severe psychiatric symptoms [36].
Similarities between mephedrone and MDMA or cocaine –
e.g., increased alertness, sexual desire, energy, entactogen
effects, and euphoria – were found by Rácz et al. [7] as well.
Among opiate-dependent patients (n= 198), most fre-
quent reasons for NPS use were curiosity, the replacement
of other drugs and easy availability [37]. Lifetime amphet-
amine use (OR = 4.64, 95% CI [2.16, 9.96]) and more
severe psychiatric symptoms (OR= 1.89, 95% CI [1.18,
3.04]) might increase the odds of synthetic cathinone use
among opiate-dependent patients.
Regarding qualitative measures, Kassai et al. [38] ana-
lysed the results of semi-structured interviews conducted
with synthetic cannabinoid users (n= 6) using the method of
interpretative phenomenological analysis. Based on the
analysis, users perceived synthetic cannabinoids as unpre-
dictable substances, with a signiﬁcant negative impact on
their inter- and intrapersonal life. The high addictive poten-
tial of synthetic cannabinoids was also described in the
users’ responses. Paranoid perceptions were marked con-
sequences of synthetic cannabinoid consumption [39].
Users also stated that synthetic cannabinoids started to take
control over their lives. Pintér et al. [40] additionally
described that synthetic cannabinoids might transform the
identity of users in a very similar way to what a trauma can
induce; thus, the use of these NPSs can be interpreted as a
form of trauma. Kapitány-Fövény et al. [41] compared the
subjective experiences regarding synthetic and natural can-
nabis consumption as a result of their qualitative research
(n= 10) and found that synthetic cannabinoids might domi-
nantly provoke adverse and unwanted effects and even
somatic withdrawal symptoms (e.g., tremors and sweating).
The effect duration of synthetic cannabinoids was shorter
than that of cannabis. Main reason for the use of this NPS
was low price and easy availability, including home
production.
Studies on toxicity and adverse consequences
Considering synthetic cathinones, MDPV toxicity was
described by various papers [42–44], mainly in the form
of case studies. Fullajtár and Ferencz [42] were the ﬁrst in
Hungary to describe a case of MDPV-induced psychosis
(case of a 34-year-old man). The observed psychotic state
was characterised by paranoid ideas and dereistic thinking.
As the patient denied the use of other types of drugs as well
as no other drug was detectable in urine sample, the
psychosis was indeed most likely induced by the consump-
tion of MDPV. Andrássy et al. [43] identiﬁed a signiﬁcant
increase in MDPV-related treatment occasions between
2010 and 2012, with 40 recorded cases related to MDPV
use. These 40 patients were registered on 87 occasions and
most importantly all these cases showed psychotic symp-
toms. Farkas et al. [44] emphasised the relevance of estab-
lishing a clear therapeutic guideline for the treatment of
patients suffering from severe MDPV (or other NPS)-
induced psychiatric symptoms by presenting ﬁve different
cases of MDPV users.
Consumption of another synthetic cathinone, methylone,
was linked to a fatal case of a 16-year-old boy [45]. Gas
chromatography/mass spectrometry was used to prove
methylone intake (272 ng/ml in blood and 387 ng/g in the
liver). As a consequence of methylone use, striated heart
muscle damage was observed. Steatosis of the heart muscle,
congenital heart disease, and bronchial asthma were listed as
potential facilitators of the drug-induced death, with relatively
low levels of methylone observed. Szily and Bitter [46]
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outlined the risks of the use of either synthetic cathinones or
cannabinoids and highlighted the importance of these NPSs
in everyday psychiatric/clinical practice.
With regard to the toxicity of synthetic cannabinoids,
Andrássy and Asztalos [47] described both the psychiatric
and organic adverse health effects of synthetic cannabi-
noids, including intense hallucinations, acute renal failure,
and developmental pathology of the embryo in the ﬁrst
2 weeks of childbearing. Cohen et al. [48] compared the
effects of synthetic cannabinoids and natural cannabis on
cognitive executive functions and found that synthetic
cannabinoid users (n= 38) performed signiﬁcantly worse
than recreational cannabis users (n= 43) or healthy controls
(n= 41) on various cognitive tests (e.g., n-back test, Stroop
word-colour task, and long-term memory task).
Hau et al. [49] presented the case of a 17-year-old drug
user with altered mental state, psychiatric symptoms, and
autonomic dysfunction caused by N-methyl-D-aspartate
(NMDA) encephalitis. Authors described that the repeated
intake of synthetic cannabinoids might lead to triggering
NMDA encephalitis “via the altered activation of the
immune system and molecular mimicry mechanism”.
Another less frequently mentioned characteristic of
synthetic cannabinoids was introduced by Hasko´ et al.
[50], stating that JWH-133 can decrease the transendothelial
migration rate of melanoma cells by activating the CB2
receptors.
DISCUSSION
Based on our literature review, ﬁrst synthetic cathinones,
then synthetic cannabinoids gained a signiﬁcant place in the
national drug scene. Legislation of these NPSs has led to a
decrease in the interest toward them, yet novel substances
arose shortly later, replacing formerly banned cathinones
and cannabinoids. The overviewed ﬁndings suggest that the
use of cathinone derivatives – such as MDPV, mephedrone,
pentedrone, or methylone – holds severe risks,
including psychotic states and fatal overdoses. Synthetic
cannabinoids – as compared to natural cannabis – may also
induce psychotic symptoms or even facilitate NMDA
encephalitis.
As a Hungarian and mainly Central-European speciﬁcity,
drug change became a marked characteristic among clients of
NEPs as well as opiate-dependent patients, resulting in
elevated frequencies of cathinone-injecting. The country’s
decreasing harm reduction efforts might further increase the
risk of such behavioural patterns. Users of either synthetic
cathinones or cannabinoids experience several adverse effects
and still prefer to maintain the consumption. This ambivalence
can be explained by practical or economical aspects: low price
and easy availability became more important factors than
psychopharmacological properties. In this new era of NPSs,
users show a rather impulsive pattern of substance use,
without considering potential risks of unknown compounds.
Nevertheless, Hungarian prevalence rates – for instance,
in the adolescent population – of synthetic cannabinoid and
cathinone use are not higher than the European average [3].
Even so, we need to emphasise that the consumption of
these NPSs is still a contemporary public health threat, and
the effective treatment of NPS users is still a challenge for
healthcare practitioners.
CONCLUSIONS
Our literature review provided a brief overview on the past
decade, focussing on the national ﬁndings regarding the use
of the most common NPSs. At present, there is available
information on epidemiology, health risks, and subjective
experience related to both cathinone derivatives and
synthetic cannabinoids; the cliché stating “we do not know
the dangers of these substances” is no longer relevant. We
have a strong body of research and empirical evidences to
start developing more effective prevention and intervention
programs as well as establishing speciﬁc therapeutic guide-
lines for the treatment of NPS users.
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